Why the study?
Whether 15-LOX is present in platelets or required for the formation of 15-oxylipins, and how these metabolites affect platelet reactivity mechanistically, remained unclear.
Population
Platelets
Comparison
Treatment with 15-oxylipins, DGLA, and enzymatic inhibitors
Design
In vitro and ex vivo preclinical experimental study
Authors
Loading...
15-oxylipins inhibit platelet reactivity independently of platelet 15-LOX; leaves open their therapeutic relevance in PUFA effects.
15-oxylipins attenuate platelet aggregation through 15-LOX-independent pathways, providing mechanistic insights into the antiplatelet effects of polyunsaturated fatty acids.
Yamaguchi et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: